Increased neutralization capacity of TNF-α in sera of relapsing remitting multiple sclerosis patients is not related to soluble TNF-α receptors or anti-TNF-α autoantibody levels

Karin Mausner-Fainberg, Keren Regev, Hadar Kolb, Adi Vaknin-Dembinsky, Arnon Karni*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The increased TNF-α levels in active lesions and CSF of multiple sclerosis (MS) patients and the beneficial effect of TNF-α blockade in animal models of MS led to the therapeutic usage of TNF-α antagonists. However, systemic TNF-α blockade exacerbated MS activity and was associated with new-onset MS when implemented for treating other autoimmune disorders. We employed a TNF-α neutralization bioassay and demonstrated that the capacity of sera from untreated and IFN-β-treated relapsing remitting MS patients to neutralize TNF-α is significantly higher than that of matched healthy controls. This finding was not related to sTNFRI, sTNFRII, or anti-TNF-α Abs levels.

Original languageEnglish
Pages (from-to)83-85
Number of pages3
JournalJournal of Neuroimmunology
Volume286
DOIs
StatePublished - 15 Sep 2015

Keywords

  • Anti-TNF-α autoantibodies
  • Multiple sclerosis
  • Soluble TNF receptors
  • TNF-α neutralization
  • Tumor necrosis factor α

Fingerprint

Dive into the research topics of 'Increased neutralization capacity of TNF-α in sera of relapsing remitting multiple sclerosis patients is not related to soluble TNF-α receptors or anti-TNF-α autoantibody levels'. Together they form a unique fingerprint.

Cite this